UPDATE 1-India's Ranbaxy beats estimates on higher sales, forex gain

Thu Nov 8, 2012 3:31pm IST

Related Topics

Stocks

   

* Net profit 7.5 bln rupees vs estimate 2.92 bln rupees

* North America sales rise 60 pct, India up 13 pct

* Foreign exchange gains at 3.93 billion rupees

MUMBAI, Nov 8 (Reuters) - Ranbaxy Laboratories Ltd , India's top drugmaker by sales, beat estimates with a 7.5 billion rupee ($140 million) quarterly net profit on stronger demand for its generic drugs in its key North American market while foreign exchange gains ballooned.

Demand for cheaper generic medicines from Ranbaxy and its local rivals such as Dr. Reddy's Laboratories Ltd, Cipla Ltd and Sun Pharmaceutical Industries Ltd is booming as developed nations battle rising healthcare costs.

Indian drugmakers, which, on average, draw half of their sales from the United States, account for about a third of applications to sell generic drugs in that country.

They, however, face intense competition, as well as an increase in lawsuits from rival drugmakers and a stricter U.S. regulatory environment.

Ranbaxy, controlled by Japan's Daiichi Sankyo Co, said on Thursday sales grew to 26.5 billion rupees in the fiscal third quarter ended September from 20.2 billion rupees a year earlier. The company gained 3.93 billion rupees in forex gains.

Analysts, on average, estimated the net profit at 2.92 billion rupees on net sales of 26.91 billion rupees, according to Thomson Reuters I/B/E/S. Ranbaxy had posted a loss of 4.65 billion in the year-ago quarter.

Last year it launched the first copy-cat version of Lipitor, the world's top-selling drug owned by Pfizer Inc, in the United States and enjoyed exclusive marketing rights with Watson Pharmaceuticals Inc for six months that ended in May 2012.

It also launched generic Actos, a diabetes drug by Takeda Pharmaceutical Co, in August and shares marketing exclusivity with Mylan Inc in the United States.

Sales in North America jumped 60 percent to 9.2 billion rupees during July-September while formulations business in India grew 13 percent to 5.83 billion rupees, it said.

Shares in Ranbaxy, valued about $4.2 billion, were up down 0.6 percent at 547.3 rupees by 0947 GMT. The stock is up nearly 35 percent this year compared with a near 20 percent rise in Mumbai market.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Healthcare Corruption

REUTERS SHOWCASE

Short of Expectations

Short of Expectations

Apple revenue lags Street's view despite strong China growth  Full Article 

Mircosoft Results

Mircosoft Results

Microsoft revenue rises, profit falls as Nokia absorbed  Full Article 

Deal Talk

Deal Talk

Exclusive - Lupin, U.S. firms weigh bids for GSK's mature drugs: sources  Full Article 

Relief For Sahara

Relief For Sahara

Supreme Court could allow Sahara boss to conduct asset sale talks, company says.  Full Article 

Classifying Banks

Classifying Banks

RBI to start announcing too-big-to-fail banks in Aug 2015  Full Article 

Food Scandal

Food Scandal

Starbucks, Burger King dragged in as China food scandal spreads.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage